Leave Your Message
Semaglutide Injection

Diabetes Mellitus

Semaglutide Injection

Semaglutide Injection is a cutting-edge treatment for adults with type 2 diabetes and is also used for weight management in individuals with obesity or overweight conditions. As a glucagon-like peptide-1 (GLP-1) receptor agonist, it significantly contributes to lowering blood sugar levels and aiding in weight loss by enhancing insulin secretion, reducing glucagon production, and delaying gastric emptying.

    product description

    Chemical Composition: 
    Semaglutide is a synthetic analog of the human GLP-1 hormone, modified to ensure stability and prolonged action in the body, facilitating once-weekly administration.
    Mechanism of Action: 
    It activates GLP-1 receptors, leading to increased insulin release in response to high blood sugar, decreased glucagon secretion, and slower gastric emptying, which helps in controlling appetite and food intake.
    Indications and Usage: 
    Approved for managing type 2 diabetes mellitus in adults to improve blood glucose levels as part of a comprehensive lifestyle program, including diet and exercise. It's also indicated for chronic weight management in adults with obesity or overweight in the presence of at least one weight-related ailment.
    Administration and Dosage: 
    Semaglutide is administered via subcutaneous injection once a week, with the dose being gradually increased to minimize gastrointestinal side effects and optimize therapeutic effects.
    Efficacy and Outcomes: 
    Clinical trials demonstrate significant improvements in HbA1c for diabetes patients and considerable weight loss for patients with obesity when used alongside diet and exercise.
    Side Effects: 
    Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and a potential risk for pancreatitis. Rarely, it may cause thyroid C-cell tumors.
    Contraindications and Precautions: 
    Not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Care should be taken in patients with a history of pancreatitis or diabetic retinopathy.

    Leave Your Message